The severity and the onset of clinical symptoms of LINCL depend upon the type of mutation, some of which cause the complete loss of functional activity, while others result in altered proteins that retain partial peptidase activity. This evidence concerns the gene LAP3 and late infantile neuronal ceroid lipofuscinosis.